INSM

INSM

USD

Insmed Incorporated Common Stock

$182.770-2.510 (-1.355%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$185.280

Máximo

$187.880

Mínimo

$182.580

Volume

1.57M

Fundamentos da empresa

Capitalização de mercado

39.0B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

2.46M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $60.4Atual $182.770Máximo $197.08

Notícias relacionadas

Analyst Upgrades

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217

Wells Fargo analyst Tiago Fauth maintains Insmed with a Overweight and raises the price target from $171 to $217.

Ver mais
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217
Analyst Upgrades

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225

Goldman Sachs analyst Andrea Tan maintains Insmed with a Buy and raises the price target from $196 to $225.

Ver mais
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $223

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $194 to $223.

Ver mais
UBS Maintains Buy on Insmed, Raises Price Target to $223
Analyst Upgrades

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215

RBC Capital analyst Leonid Timashev maintains Insmed with a Outperform and raises the price target from $139 to $215.

Ver mais
RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215
Analyst Upgrades

B of A Securities Maintains Buy on Insmed, Raises Price Target to $187

B of A Securities analyst Jason Zemansky maintains Insmed with a Buy and raises the price target from $142 to $187.

Ver mais
B of A Securities Maintains Buy on Insmed, Raises Price Target to $187
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $194

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $140 to $194.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.